CA2508581A1 - Spirocyclic ureas, compositions containing such compounds and methods of use - Google Patents

Spirocyclic ureas, compositions containing such compounds and methods of use Download PDF

Info

Publication number
CA2508581A1
CA2508581A1 CA002508581A CA2508581A CA2508581A1 CA 2508581 A1 CA2508581 A1 CA 2508581A1 CA 002508581 A CA002508581 A CA 002508581A CA 2508581 A CA2508581 A CA 2508581A CA 2508581 A1 CA2508581 A1 CA 2508581A1
Authority
CA
Canada
Prior art keywords
groups
optionally substituted
halo
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002508581A
Other languages
English (en)
French (fr)
Inventor
Emma R. Parmee
Fengqi Zhang
Dong-Ming Shen
John Stelmach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2508581A1 publication Critical patent/CA2508581A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002508581A 2002-12-04 2003-11-26 Spirocyclic ureas, compositions containing such compounds and methods of use Abandoned CA2508581A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43079902P 2002-12-04 2002-12-04
US60/430,799 2002-12-04
PCT/US2003/038590 WO2004050039A2 (en) 2002-12-04 2003-11-26 Spirocyclic ureas, compositions containing such compounds and methods of use

Publications (1)

Publication Number Publication Date
CA2508581A1 true CA2508581A1 (en) 2004-06-17

Family

ID=32469534

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002508581A Abandoned CA2508581A1 (en) 2002-12-04 2003-11-26 Spirocyclic ureas, compositions containing such compounds and methods of use

Country Status (6)

Country Link
US (1) US20060116366A1 (enExample)
EP (1) EP1569915A4 (enExample)
JP (1) JP2006509015A (enExample)
AU (1) AU2003298889A1 (enExample)
CA (1) CA2508581A1 (enExample)
WO (1) WO2004050039A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2513102C (en) 2003-01-27 2011-03-22 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
SI1756064T1 (sl) 2004-06-04 2008-12-31 Merck & Co Inc Derivati pirazola, sestavki vsebujoäśi takĺ ne sestavine in postopki uporabe
US7649009B2 (en) 2004-07-07 2010-01-19 Merck & Co., Inc. Pyrazole amide derivatives, compositions containing such compounds and methods of use
ATE468853T1 (de) 2004-07-22 2010-06-15 Merck Sharp & Dohme Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
CN101238124A (zh) 2005-07-18 2008-08-06 默克公司 用于治疗阿尔茨海默氏病的螺哌啶β-分泌酶抑制剂
US7709658B2 (en) 2005-07-26 2010-05-04 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
WO2007111864A2 (en) 2006-03-23 2007-10-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007136577A2 (en) 2006-05-16 2007-11-29 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2008054698A2 (en) 2006-10-30 2008-05-08 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
EP2786985B1 (en) 2007-02-09 2018-11-28 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
CN104803891B (zh) 2008-08-13 2017-10-20 症变治疗公司 胰高血糖素拮抗剂
US20130012434A1 (en) * 2010-03-25 2013-01-10 Wong Michael K Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use
EP2552209A4 (en) * 2010-03-26 2014-01-22 Merck Sharp & Dohme NEW SPIROIMIDAZOLON DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHOD FOR THEIR USE
JP2014040374A (ja) * 2010-12-15 2014-03-06 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害物質
RU2013127611A (ru) 2010-12-23 2015-01-27 Пфайзер Инк. Модуляторы глюкагонового рецептора
MX2013009140A (es) 2011-02-08 2013-10-01 Pfizer Moduladores del receptor de glucagon.
RU2013157388A (ru) 2011-07-22 2015-08-27 Пфайзер Инк. Хинолинильные модуляторы глюкагонового рецептора
US8742111B1 (en) * 2013-02-21 2014-06-03 The United States Of America As Represented By The Secretary Of The Army Synthesis of intermediate anilino methyl esters used in the production of synthetic opioid analgesics
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
ES2829550T3 (es) * 2016-07-07 2021-06-01 Bristol Myers Squibb Co Ureas cíclicas espiro-condensadas como inhibidores de ROCK
CA3030788A1 (en) * 2016-07-18 2018-01-25 F. Hoffmann-La Roche Ag Ethynyl derivatives
TW202003453A (zh) 2018-02-13 2020-01-16 美商利根德製藥公司 升糖素受體拮抗劑
WO2021078132A1 (en) * 2019-10-21 2021-04-29 Sironax Ltd Inhibitors of mtor-mediated induction of autophagy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556670A (en) * 1982-12-06 1985-12-03 Pfizer Inc. Spiro-3-hetero-azolones for treatment of diabetic complications
FR2677984B1 (fr) * 1991-06-21 1994-02-25 Elf Sanofi Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
DE4201709A1 (de) * 1992-01-23 1993-07-29 Bayer Ag (alpha)-aryl-(alpha)-hydroxy-ss-imidazolinyl-propionsaeureamide
US6384061B1 (en) * 1997-07-26 2002-05-07 Lg Chemical Ltd. Hydantoin compounds and methods related thereto
KR19990012061A (ko) * 1997-07-26 1999-02-25 성재갑 파네실 전이효소 저해제로 유용한 하이덴토인 유도체

Also Published As

Publication number Publication date
AU2003298889A1 (en) 2004-06-23
EP1569915A4 (en) 2007-07-11
WO2004050039A2 (en) 2004-06-17
WO2004050039A3 (en) 2004-07-29
US20060116366A1 (en) 2006-06-01
EP1569915A2 (en) 2005-09-07
JP2006509015A (ja) 2006-03-16

Similar Documents

Publication Publication Date Title
CA2508581A1 (en) Spirocyclic ureas, compositions containing such compounds and methods of use
US7803951B2 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AU2004210127B2 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
US7649009B2 (en) Pyrazole amide derivatives, compositions containing such compounds and methods of use
US7301036B2 (en) Cyclic guanidines, compositions containing such compounds and methods of use
AU2005269792B2 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
JP2006528687A (ja) ベンズイミダゾール、こうした化合物を含有する組成物および使用方法
US7598398B2 (en) Acyl indoles, compositions containing such compounds and methods of use
AU2007229850A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CA2650619A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7563815B2 (en) Benzamidazoles, compositions containing such compounds and methods of use

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued